Potent ß-lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates

UDC.coleccionInvestigación
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicas
UDC.grupoInvInvestigación en Microbiología (INIBIC)
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue11
UDC.journalTitleAntimicrobial Agents and Chemotherapy
UDC.volume61
dc.contributor.authorMoya, Bartolomé
dc.contributor.authorBarceló, Isabel M.
dc.contributor.authorBhagwat, Sachin
dc.contributor.authorPatel, Mahesh
dc.contributor.authorBou, Germán
dc.contributor.authorPapp-Wallace, Krisztina M.
dc.contributor.authorBonomo, Robert
dc.contributor.authorOliver, Antonio
dc.date.accessioned2026-04-22T09:21:43Z
dc.date.available2026-04-22T09:21:43Z
dc.date.issued2017-08-28
dc.description.abstract[Abstract] Multidrug-resistant Acinetobacter baumannii has rapidly spread worldwide, resulting in a serious threat to hospitalized patients. Zidebactam and WCK 5153 are novel non-β-lactam bicyclo-acyl hydrazide β-lactam enhancer antibiotics being developed to target multidrug-resistant A. baumannii The objectives of this work were to determine the 50% inhibitory concentrations (IC50s) for penicillin-binding proteins (PBP), the OXA-23 inhibition profiles, and the antimicrobial activities of zidebactam and WCK 5153, alone and in combination with β-lactams, against multidrug-resistant A. baumannii MICs and time-kill kinetics were determined for an A. baumannii clinical strain producing the carbapenemase OXA-23 and belonging to the widespread European clone II of sequence type 2 (ST2). Inhibition of the purified OXA-23 enzyme by zidebactam, WCK 5153, and comparators was assessed. All of the compounds tested displayed apparent Ki values of >100 μM, indicating poor OXA-23 β-lactamase inhibition. The IC50s of zidebactam, WCK 5153, cefepime, ceftazidime, meropenem, and sulbactam (range of concentrations tested, 0.02 to 2 μg/ml) for PBP were also determined. Zidebactam and WCK 5153 demonstrated specific high-affinity binding to PBP2 of A. baumannii (0.01 μg/ml for both of the compounds). The MICs of zidebactam and WCK 5153 were >1,024 μg/ml for wild-type and multidrug-resistant Acinetobacter strains. Importantly, combinations of cefepime with 8 μg/ml of zidebactam or WCK 5153 and sulbactam with 8 μg/ml of zidebactam or WCK 5153 led to 4- and 8-fold reductions of the MICs, respectively, and showed enhanced killing. Notably, several of the combinations resulted in full bacterial eradication at 24 h. We conclude that zidebactam and WCK 5153 are PBP2 inhibitors that show a potent β-lactam enhancer effect against A. baumannii, including a multidrug-resistant OXA-23-producing ST2 international clone.
dc.description.sponsorshipThis work was supported by Wockhardt Bio AG, Switzerland, and by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (ERDF; A Way To Achieve Europe), through the Spanish Network for Research in Infectious Diseases (RD12/0015 and RD16/0016). The research reported in this publication was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs to K.M.P.-W. and R.A.B., Veterans Affairs Merit Review Program award 1I01BX002872 to K.M.P.-W., and Veterans Affairs Merit Review Program award 1I01BX001974 to R.A.B. from the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Service and by the Geriatric Research Education and Clinical Center VISN 10 to R.A.B. R.A.B. is also supported by the Harrington Foundation and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R21AI114508, R01AI100560, R01AI063517, and R01AI072219.
dc.identifier.citationMoya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver A. Potent ß-lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01238-17.
dc.identifier.doi10.1128/AAC.01238-17
dc.identifier.issn1098-6596
dc.identifier.urihttps://hdl.handle.net/2183/48063
dc.language.isoeng
dc.publisherAmerican Society for Microbiology
dc.relation.projectIDR
dc.relation.urihttps://doi.org/10.1128/AAC.01238-17
dc.rights.accessRightsopen access
dc.subjectMDR A. baumannii
dc.subjectPBP IC50
dc.subjectWCK 5153
dc.subjectZidebactam
dc.subjectβ-lactam enhancer.
dc.titlePotent ß-lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates
dc.typejournal article
dc.type.hasVersionAM
dspace.entity.typePublication
relation.isAuthorOfPublication909e08d1-6ed1-4b99-9e9e-c64eb72e7dea
relation.isAuthorOfPublication.latestForDiscovery909e08d1-6ed1-4b99-9e9e-c64eb72e7dea

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Moya_Potent β_2017.pdf
Size:
729.38 KB
Format:
Adobe Portable Document Format